Category: Uncategorized

Most pharmaceutical companies spend months preparing for an FDA inspection. SOPs reviewed. Batch records organized. Staff trained.

And then an Investigator walks in unannounced on a Tuesday morning and the first thing they notice has nothing to do with any of it.

I spent 14 years as an FDA Investigator. I have walked into hundreds of facilities. I know exactly what happens in the first 30 minutes of an inspection — and I can tell you that what happens in those first 30 minutes shapes everything that follows.

FDA inspections are not won or lost during the inspection itself. They are won or lost in the decisions your team makes before an Investigator ever arrives, and in the critical hours after they leave.

What Most Companies Get Wrong

The standard inspection preparation advice is not wrong. It is just incomplete.

Document control, SOP currency, CAPA closure rates — these are the baseline. Every company that gets a Warning Letter had SOPs. Every company that receives an OAI classification had trained staff. Procedures on paper do not determine inspection outcomes. Execution under pressure does.

The companies that navigate FDA inspections successfully understand something that most compliance training programs never teach: FDA Investigators are evaluating your quality culture from the moment they badge in. They are drawing conclusions about organizational control, management commitment, and system reliability before a single document is requested.

By the time your most senior quality leader sits down across from the Investigator, a preliminary picture has already been formed.

The First 30 Minutes Matter More Than You Think

An unannounced inspection gives you no time to prepare in the moment. What you can control is how your team responds when it happens.

How long the Investigator waits at reception. Who greets them and who is suddenly unavailable. Whether your opening meeting is structured and confident or improvised and reactive. Whether your document retrieval is smooth or visibly scrambled.

None of these things appear on a 483. All of them influence how an Investigator characterizes what they find.

The gap between a routine inspection and a for-cause inspection is often not the severity of the deficiencies. It is the confidence an Investigator develops — or loses — in your organization’s ability to control its own systems.

What Happens After the Investigator Leaves

The inspection does not end when the Investigator walks out the door. What your team does in the hours and days that follow, how you respond to observations, how you engage with the district office, how you manage the classification process has a direct impact on whether your inspection results in routine follow-up or regulatory escalation.

Most companies treat the post-inspection period as a waiting game. Experienced companies treat it as the most important phase of the entire inspection cycle.

The Five Strategies

There are five specific insider strategies — drawn from 14 years of FDA field experience and 13 years on the industry side — that address every phase of the inspection cycle: the first 30 minutes, document management, 483 interpretation, closeout meeting intelligence, and post-inspection classification influence.

None of them are in your SOP manual. None of them are taught in standard GMP training. They reflect how FDA’s inspection system actually operates — from the inside.

They are in The Investigator’s Lens.

Read the full article here: https://devaughnedwards.substack.com/p/five-fda-insider-tips-for-handling?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

In March 2026, FDA issued a Warning Letter to Novo Nordisk Inc. following an inspection that concluded in February 2025.

Most compliance teams will read this letter and focus on the specific observations. That is the wrong way to read it.

I spent 14 years as an FDA Investigator. I wrote 483s. I conducted follow-up inspections after Warning Letters. When I read this letter, what I see is not a list of findings. I see a company that FDA no longer trusts to operate a critical patient safety system without regulatory intervention.

That is a very different problem than a documentation gap.

What FDA Actually Found

The Warning Letter targets Novo Nordisk’s postmarketing adverse event reporting system — the pharmacovigilance function responsible for detecting, evaluating, and reporting safety signals after a drug reaches patients.

FDA did not find one broken process. They found failures across multiple connected functions at the same time. Case intake. Investigation adequacy. Medical review. Vendor oversight. CAPA.

When that many elements fail together, FDA draws one conclusion: the system itself cannot be relied upon to protect patients. That conclusion is what drives everything that happens next — and what happens next is significantly more serious than the Warning Letter itself.

Why This Should Concern Your Organization

Novo Nordisk is not a small company with an immature quality system. They are one of the largest pharmaceutical manufacturers in the world. If a pharmacovigilance failure of this scope can happen there, it can happen anywhere.

The vulnerabilities FDA identified in this letter are not unique to Novo Nordisk. They exist across the industry — at large manufacturers, at CDMOs, at organizations that have never failed a routine inspection and have no reason to believe they are at risk.

The difference between a company that receives a Warning Letter and one that does not is rarely the quality of their written procedures. It is whether the system actually performs under real operating conditions, with real vendors, processing real cases at real volume.

Most organizations do not find out their system has a problem until an Investigator documents it.

What Comes After a Warning Letter Like This

A Warning Letter is not the end of the regulatory action. It is the beginning of an escalating sequence that most companies are not prepared for.

Based on the language and scope of this letter, the follow-up will be aggressive. FDA does not return to a site after a pharmacovigilance Warning Letter to check paperwork. They return to determine whether the system behaves differently — and they test that conclusion against actual cases, actual timelines, and actual vendor performance data.

If the answer is no, the options available to FDA go well beyond another letter.

The Full Intelligence — What To Do Before FDA Comes to You

Knowing what went wrong at Novo Nordisk is useful. Knowing exactly how FDA will evaluate your system when they arrive, what they will ask for first, what patterns they are trained to identify, and how to conduct your own mock inspection before they do — that is what protects your organization.

That intelligence is in the paid edition of The Investigator’s Lens. Written by a former FDA Investigator who conducted exactly this type of inspection. Not a compliance consultant’s interpretation of a warning letter. The actual methodology, from the inside.

Read the full article here:
https://devaughnedwards.substack.com/p/novo-nordisk-warning-letter-march?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

Most FDA inspection failures are not technical. The deficiencies get written up, sure. But what turns a manageable inspection into a Warning Letter situation is almost always behavioral.

I spent 14 years as an FDA Investigator. I walked into hundreds of facilities. I wrote the 483s. I filed the Establishment Inspection Reports that determined whether a company got a routine follow-up or an OAI classification.

What I can tell you is this: Investigators arrive at your facility having already read your history. They know your prior 483 observations, your Warning Letters, your commitments to the Agency. What they do not yet know is how your team will behave over the next several days.

That behavior shapes everything that follows.

The Five Offenses

There are five specific behaviors that reliably escalate inspections from routine to adversarial. None of them are technical. All of them are avoidable. And every one of them sends the same signal to a trained Investigator.

The signal is: this company is managing perception rather than demonstrating compliance.

When an Investigator picks up that signal, they dig. And when they dig, they find things.

What these five behaviors have in common is that they tell an Investigator, with considerable precision, exactly where to look. The harder a company works to steer, delay, or deflect, the more certain the Investigator becomes that steering, delay, and deflection are necessary.

I have seen all five of these behaviors in facilities that had perfectly adequate quality systems on paper. The paper did not save them.

Why This Matters More Than Your SOP Manual

Standard inspection preparation focuses on documents. Procedures. Batch records. CAPA closure rates. Training logs.

None of that preparation addresses what actually determines whether an Investigator leaves your facility with a short list of minor observations or a narrative that reads like a systemic breakdown.

The companies that consistently navigate FDA inspections well are not always the most technically compliant. They are the ones whose teams understand how the inspection dynamic actually works — and behave accordingly from the moment an Investigator presents credentials at the front desk.

That understanding is not in your SOP manual. It is not covered in standard GMP training. It comes from having been on the other side of the table.

The Full Article Is in The Investigator’s Lens

All five offenses — with the specific Investigator response each one triggers and exactly what your team should do instead — are in the paid edition of The Investigator’s Lens.

Written by a former FDA Investigator who has watched every version of these mistakes play out in real inspections. Not a compliance consultant’s interpretation. The actual experience, from the inside.

Read the full article here: https://devaughnedwards.substack.com/p/how-to-piss-off-an-fda-investigator?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831